To the oldest corporate venture groups such as the Novartis Venture Fund, the idea of sitting alongside conventional venture capitalists to organise funding for a young research-intensive company is nothing new. Novartis has been doing it for more than 14 years and now has dedicated teams in Basel, Switzerland and Cambridge Massachusetts to vet life science assets, as well as a three-year old options fund to invest in some very early stage companies.
